David McErlane - 25 Oct 2023 Form 3 Insider Report for Catalent, Inc.

Role
Group President, Biologics
Signature
/s/ Amy Fallone, attorney-in-fact
Issuer symbol
N/A
Transactions as of
25 Oct 2023
Net transactions value
$0
Form type
3
Filing time
02 Nov 2023, 21:17:01 UTC
Next filing
30 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTLT Common Stock 19,552 25 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTLT Options to purchase Common Stock 25 Oct 2023 Common Stock 14,740 $45.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units, each representing the right to receive one share of Issuer's common stock as of the date of vesting, which is scheduled to occur in three equal annual installments beginning on September 25, 2024.
F2 The options vest and become exercisable in four equal annual installments beginning on September 25, 2024.